Neil Gregory Almstead

Chief Technical Ops Officer Neil Gregory Almstead sells 46,774 shares (43.7% of pre-transaction holdings) for $4,093,481.61 via 8 transactions on 2026-07-06/07

Neil Gregory Almstead executed 8 separate sales totaling 46,774 shares for $4,093,481.61 across July 6–7, 2026, reducing his non-derivative holdings from 107,073 to 60,299 shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-11, making it a scheduled sale rather than a discretionary trade. The blended average price of $87.52 compares closely to the current price of $88.57 and sits near the 52-week high of $89.85. PTCT's fundamentals show revenue growth of +114.5% year-over-year alongside a net loss of $-2,809,000 in the latest quarter, reflecting a high-growth biotech profile. The insider retains 61,615 derivative securities (stock options) across four vehicles, preserving significant upside exposure while harvesting proceeds from the non-derivative tranche. The cross-ticker track record shows negative average 90-day returns of -7.1% following prior sales, though this transaction's scheduled nature removes timing as an interpretive factor.

Chief Technical Ops Officer Neil Gregory Almstead sold 26,283 shares (26.3K shares) for $2,254,463.35 ($2.3M) via 7 transactions at PTCT, per 10b5-1 plan

Neil Gregory Almstead, Chief Technical Ops Officer, executed 7 separate sales totaling 26,283 shares for $2,254,463.35 on 2026-06-24 and 2026-06-25 at an average price of $85.78, reducing non-derivative holdings by 30.4% to 60,137 shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-11, meaning the sales were scheduled and not discretionary. Almstead retains 213,919 shares in derivative holdings (stock options) across five tranches, preserving meaningful future upside exposure. His prior PTCT-specific sales (5 trades dating to late 2025 and early 2026) showed modest negative returns in the 30-day and 90-day periods post-sale, with 90-day outcomes ranging from -15.5% to -16.7% when measured. The stock currently trades at $84.43, down 3.5% from its 52-week high of $87.50 and up 19.5% over the prior 30 days and 27.7% over the prior 90 days, reflecting recent positive momentum. PTCT's fundamentals show strong annual revenue growth of 114.5%, though the company is currently unprofitable with a net loss of $2,809,000 on revenue of $272,551,000.

Neil Gregory Almstead (CTO) sold 23,749 shares at $80.90 avg for $1.9M via scheduled 10b5-1 plan

Neil Gregory Almstead, Chief Technical Operations Officer, executed 2 separate sales totaling 23,749 shares for $1,921,378.29 on 2026-06-22 pursuant to a pre-arranged 10b5-1 trading plan adopted on 2025-11-11. His non-derivative holdings decreased 28.3% from 83,886 shares to 60,137 shares; however, he retains 23,751 stock options (derivative securities) in Table II. The stock has appreciated +22.7% over 30 days and +26.0% over 90 days, currently trading at $84.41, which is -3.5% from its 52-week high of $87.50. At PTCT specifically, his prior 5 open-market trades show 30-day returns ranging from -7.4% to -5.4%, with the two measurable 90-day outcomes at -16.7% and -15.5%. This transaction is scheduled, not discretionary, under the 10b5-1 framework.

PTC Chief Technical Ops Officer Neil Gregory sells 52,003 shares for $3.6M via 10b5-1 plan

Neil Gregory, Chief Technical Operations Officer, executed 3 separate sales totaling 52,003 shares for $3,590,242.77 at a blended average price of $69.04 on 2026-04-01. This transaction reduced his holdings by 46.4%, from 112,140 shares to 60,137 shares post-transaction. The sales were conducted pursuant to a 10b5-1 trading plan adopted on 2025-11-11, indicating these were scheduled, non-discretionary transactions rather than discretionary trades responsive to current market conditions. While the substantial reduction in personal shareholding is notable from a stake-size perspective, the pre-arranged plan structure removes any inference about current timing decisions or conviction regarding the stock's near-term direction.

Chief Technical Ops Officer Almstead sells 35,572 shares for $2.9M at PTCT via scheduled 10b5-1 plan adopted 2024-12-10

Almstead Neil Gregory, Chief Technical Operations Officer at PTC Therapeutics, executed five separate sales totaling 35,572 shares on 2025-11-24 for $2,852,030.56, reducing his holdings from 136,197 to 100,625 shares (-26.1%). The shares were sold at prices ranging from $80.14 to $80.19, with a blended average of $80.18. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2024-12-10, indicating the sale was scheduled and not discretionary. The scale of the reduction—over one-quarter of his pre-transaction stake—represents a material change in his equity position, though the prearrangement limits inference about current convictions or market timing.

PTCT Chief Technical Ops Officer sells 71,928 shares for $6.0M via 10b5-1 plan

Almstead Neil Gregory executed 19 separate sales totaling 71,928 shares for $6,001,932.05 on 2025-11-25, reducing his holdings from 172,553 shares to 100,625 shares (a -41.7% reduction). The sales occurred at prices ranging from $82.55 to $85.37 with a blended average price of $83.44. Critically, this transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2024-12-10, meaning the sales were scheduled and not discretionary. The large volume and consistent execution across multiple price points is consistent with the systematic nature of a 10b5-1 plan. Without additional context on the plan's terms, duration, or frequency, the sale reflects automatic portfolio liquidation under a predetermined framework rather than a direct signal about current business conditions or executive conviction.

PTCT CTO Neil Gregory executes 6 sales totaling 55,000 shares for $3,632,976.72 under pre-arranged 10b5-1 plan adopted 2024-12-10

Chief Technical Operations Officer Neil Gregory sold 55,000 shares (35.3% reduction of pre-transaction holdings) across 6 separate transactions on 2025-10-03, with prices ranging from $65.45 to $67.16 and a blended average of $66.05. This sale is part of a pre-arranged 10b5-1 trading plan adopted on 2024-12-10, meaning the transaction was scheduled and not discretionary. Post-transaction holdings stand at 100,625 shares. Since the sale is governed by a 10b5-1 plan, it reflects a pre-determined disposal schedule established months prior rather than a response to current market conditions or recent operational developments at PTC Therapeutics.

Chief Technical Ops Officer Neil Gregory sold 71,610 shares for $3.7M under pre-arranged 10b5-1 plan

Neil Gregory, Chief Technical Ops Officer at PTC Therapeutics, executed 6 separate sales totaling 71,610 shares for $3,727,957.62 on 2024-12-02, reducing his holdings from 76,186 shares to 4,576 shares. This sale was conducted under a 10b5-1 trading plan adopted on 2023-02-21, meaning it was pre-arranged and scheduled rather than a discretionary trade decision. The magnitude of this activity—eliminating 94.0% of his prior position—combined with the executive's senior operational role merits attention, though the scheduled nature of the transaction limits inference about current conviction regarding the stock's near-term direction.